Cognition Therapeutics is a clinical-stage biopharmaceutical company. Co. is developing a pipeline of small molecule product candidates that are designed to target the o-2 (sigma-2) receptor (S2R) complex, a key regulator of the cellular damage response for diseases such as Alzheimer's disease, dry Age-Related Macular Degeneration (AMD), geographic atrophy (a form of dry AMD), and other conditions. Co.'s main product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex. Co. is initially focused on the development of CT1812 for the treatment of AD by targeting the accumulation of B-amyloid. We show 6 historical shares outstanding datapoints in our CGTX shares outstanding history coverage, used to compute CGTX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CGTX market cap history over the course of time is important for investors
interested in comparing CGTX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CGTX versus a peer is one thing; comparing
CGTX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CGTX can fluctuate over the course of history.
With this page we aim to empower investors researching CGTX by allowing them to research the CGTX market cap history. |
Free CGTX Email Alerts:
Video: The Importance of Market Cap
